Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
K12 + liposomal glutathione
- Development stage
- Phase 1
- Modality
- Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
K12 + liposomal glutathione is a combination formulation containing two components: K12 (which, based on context and available evidence, is most likely *Streptococcus salivarius K12*, a probiotic strain) and *liposomal glutathione*, a highly bioavailable form of the antioxidant glutathione encapsulated in liposomes. - **K12** (Streptococcus salivarius K12) is used as an oral probiotic, primarily for supporting oral and upper respiratory health, by producing bacteriocins that inhibit pathogenic microorganisms. - **Liposomal glutathione** enhances the delivery and absorption of glutathione, an endogenous tripeptide that acts as a key antioxidant, supports immune function, and participates in detoxification processes. Glutathione acts as a cofactor for glutathione peroxidase, participates in leukotriene synthesis, and plays a critical role in hepatic biotransformation and detoxification. Liposomal delivery may increase body stores and impact immune markers such as lymphocyte proliferation and NK cell activity[4][7]. - This combination is marketed as a dietary supplement aiming to provide oral and systemic health benefits via immune support, antioxidant effects, and microbial modulation.
- Brand names
- K12 + liposomal glutathione
- Other names
- K12 + liposomal glutathione
02
Targets
GLO1 (Glyoxalase 1)HAGH (Hydroxyacylglutathione hydrolase)GPX4 (Glutathione peroxidase 4)MRP (Multidrug resistance-associated protein family)
Beyond the preview
Go deeper on K12 + liposomal glutathione.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on K12 + liposomal glutathione.